This contrasts with the literature on GPCR overexpression in other tumors, such as neuroendocrine neoplasms, where overexpression of somatostatin receptors and the receptor for gastric inhibitory polypeptide may be variable or reduced in G3 tumors in contrast to G1 and G2 tumors [73,74]. The gene discussed is GIP; the disease is neuroendocrine neoplasm.